# ORM-5029

Source: https://onco.cc/drugs/orm-5029/  
OnCo record `orm-5029` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for HER2-expressing advanced solid tumours, including HER2-positive breast cancer; development has stopped.

## Summary

ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics. A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells. Its furthest stage is phase 1, for HER2-expressing advanced solid tumours, including HER2-positive breast cancer. ClinicalTrials.gov registers it in one study linked below. Orum discontinued clinical development of ORM-5029 (company release of 28 April 2025). The phase 1 NCT05511844 is TERMINATED ('Sponsor Decision'). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest; discontinued
- Code: ORM-5029
- Modality: Degrader-antibody conjugate
- Mechanism: A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells.

## Sources

- Orum Therapeutics: 1stoncology.com: https://www.1stoncology.com/blog/?p=102707
- Orum Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT05511844
- ClinicalTrials.gov: trials of ORM-5029: https://clinicaltrials.gov/search?intr=ORM-5029

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)
- trials: [Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors](https://onco.cc/trials/nct05511844/)

---
JSON: https://onco.cc/api/v1/entities/orm-5029.json